
How RSV manipulates the immune response in respiratory cells
TWINCORE researchers investigate gene activity in host cells

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
This year's TWINCORE Symposium will take place on 3 - 4 September.

TWINCORE researchers investigate gene activity in host cells

Diverse Origins – One Goal

The 23rd doctoral thesis to receive an award at TWINCORE
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Vandenabeele L, Ayanwale A, Pietschmann T, Nilsson-Payant B
Dinkelborg K, Niehaus C, Bremer B, Wundes C, Tiede A, Petruch N, Deterding K, Kraft A, Hartleben B, Cornberg M, Wedemeyer H, Behrendt P, Maasoumy B
Berg K, Haid S, Vafadarnejad E, Carpentier A, Geffers R, Wiegmann B, Saliba A, Erhard F, Pietschmann T
The project will investigate the immunological and genetic causes of vaccination failure in 5% of HBV-vaccinated individuals in order to develop new strategies to improve vaccination protection.
Studies in the cell culture model show that only a few disinfectants are effective against HEV, which provides important information on hygiene measures for HEV infections. We are also working together to test vaccines for pigs as HEV reservoirs.
We are investigating how genetic variants influence the risk of severe RSV infections in infants. Exome sequencing and bioinformatic analyses are used to identify causal variants in immunity genes.
Monoclonal antibodies are transforming modern medicine. At Helmholtz Infection Medicine at MHH, bringing together TWINCORE and CiiM, advanced technologies and AI drive the development of next-generation human antibodies against major infectious diseases.

